Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE
NCT06072898Phase 2Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Sunnybrook Health Sciences Centre. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06072898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072898.